Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: A randomized trial

JAMA

Volumn 292, Issue 2, 2004, Pages 180-190

  Saag, Michael S ^b   Cahn, Pedro ^c   Raffi, François ^d   Wolff, Marcelo ^e   Pearce, Daniel ^f   Molina, Jean Michel ^g   Powderly, William ^h   Shaw, Audrey L ^a   Mondou, Elsa ^a   Hinkle, John ^a   Borroto Esoda, Katyna ^a   Quinn, Joseph B ^a   Barry, David W ^a   Rousseau, Franck ^a  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c FUNDACIÓN HUÉSPED   (Argentina)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e HOSPITAL SAN BORJA ARRIARÁN   (Chile)

^f AltaMed Health Services   (United States)

^g SAINT LOUIS HOSPITAL   (France)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; GLUCOSE; NELFINAVIR; STAVUDINE; TRIACYLGLYCEROL LIPASE; VIDEX EC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; OXAZINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANTHROPOMETRY; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EUROPE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; KAPLAN MEIER METHOD; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER DYSFUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NIGHTMARE; NORTH AMERICA; OPEN STUDY; PANCREATITIS; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SKIN DISCOLORATION; SOUTH AND CENTRAL AMERICA; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VIVID DREAM; VOMITING; COMPARATIVE STUDY; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEOXYCYTIDINE; DIDANOSINE; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OXAZINES; STAVUDINE; VIRAL LOAD;

EID: 3142697068     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.2.180     Document Type: Article

References (33)

1. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001; 15:1369-1377.
2. Frank I. Once-daily HAART. J Acquir Immune Defic Syndr. 2002;31:S10-S15.
3. Richman DD. Antiviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Therapy. 2001;6:83-88.
4. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90:5653-5656.
5. Schinazi RF, McMillan A, Cannon D, et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2- (hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992;36:2423-2431.
6. Cahn P. Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. Expert Opin Investig Drugs. 2004;13:55-68.
7. Wang LW, Begley J, St Claire RL, et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses. 2004. In press.
8. Schinazi RF, Lloyd RM, Nguyen M-H, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine. Antimicrob Agents Chemother. 1993;37:875-881.
9. Rousseau FS, Kahn JO, Thompson M, et al. Prototype trial design for rapid selection of antiretroviral drugs. J Antimicrob Chemother. 2001;48:507-513.
10. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302-1307.
11. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995;373:117-122.
12. Molina J-M, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000;182:599-602.
13. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo.nih.gov. Accessed June 14, 2004.
14. Amplicor HIV-1 Monitor Test version 1.0 [package insert]. Branchburg, NJ: Roche Molecular Systems Inc; 1999.
15. Amplicor HIV-1 Monitor Test version 1.5 [package insert]. Branchburg, NJ: Roche Molecular Systems Inc; 2002.
16. AIDS Clinical Trial Group. Division of AIDS table for grading severity of adult adverse experiences. Rockville, Md: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996.
17. Division of Antiviral Drug Products, Office of Drug Evaluation IV, Center for Drug Evaluation and Research (CDER), Food and Drug Administration. Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements-Clinical Considerations for Accelerated and Traditional Approval. Available at: http://www.fda.gov/cder/guidance/3647fnl.pdf Accessed June 18, 2004.
18. 1993 Revised classification system for HIV infection and expanded surveillance case definitions for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
19. Wilson JW, Bean P, Robins T, et al. Comparative evaluation of three human immunodeficiency virus genotyping systems. J Clin Microbiol. 2000;38:3022-3028.
20. Erali M, Page S, Reimer L, et al. Human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol. 2001;39:2157-2165.
21. Shafer R. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev. 2002;15:247-277.
22. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy. Antivir Ther. 2000; 5:41-48.
23. Molina J-M, Ferchal F, Journot V, et al. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment-naive HIV-infected adults. Presented at: 8th European Conference on Clinical Aspects and Treatment of HIV Infection; October 28-31, 2001; Athens, Greece. Abstract 221.
24. Stein A, Luskin-Hawk R, Pegram S, et al. Efficacy of efavirenz (EFV) in combination with stavudine (d4T) and didanosine (ddl) in antiretroviral therapy-naive HIV-infected patients (Study 044). Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco, Calif. Abstract 1982.
25. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.
26. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-1430.
27. Powderly W, Cahn P, Raffi F, et al. Lipid abnormalities and body habitus in a double-blind, randomized, controlled trial comparing emtricitabine to stavudine in HIV+ ART-naive patients. Presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, Calif. Abstract 717.
28. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy. Clin Infect Dis. 2003; 37:613-627.
29. Le Moing V, Chene G, Carrieri MP, et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS. 2002;16:21-29.
30. Duran S, Spire B, Raffi F, etal. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients. HIV Clin Trials. 2001;2:38-45.
31. Sanne I, Saag M, Shaw A, et al. Efficacy of emtricitabine (FTC) in HIV-infected patients with high pretreatment viral load. Presented at: 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract 546.
32. Robbins G, DeGruttola V, Shafer R, et al. Comparisons of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349: 2293-2303.
33. Staszewski S, Gallant J, Pozniak A, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 4B-week interim results. In: Program and Abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract LbOr17.